SKINOVATION PHARMACEUTICAL INCORPORATED: 10-Q filed 2019-08-09

Name: SKINOVATION PHARMACEUTICAL INCORPORATED: 10-Q filed 2019-08-09
Creator: SKINOVATION PHARMACEUTICAL INCORPORATED

What SKINOVATION PHARMACEUTICAL INCORPORATED reported in its quarterly report filed 2019-08-09 (fiscal Q2 2019): 18 published measures, 56 facts as tagged in accession 0001554795-19-000234.

This filing

Form: 10-Q (quarterly report)
Filed: 2019-08-09
Fiscal period: fiscal Q2 2019
Accession: 0001554795-19-000234 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SKINOVATION PHARMACEUTICAL INCORPORATED filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2019-06-30	107	USD
At 2018-12-31	132	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2019-06-30	300,663	USD
At 2018-12-31	284,590	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2019-06-30	-300,556	USD
At 2019-03-31	-293,825	USD
At 2018-12-31	-284,458	USD
At 2018-06-30	-271,581	USD
At 2018-03-31	-265,173	USD
At 2017-12-31	-255,870	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2019-06-30	107	USD
At 2018-12-31	132	USD
At 2018-06-30	162	USD
At 2017-12-31	547	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	-6,731	USD	91
2019-01-01 to 2019-06-30	-16,098	USD	181
2019-01-01 to 2019-03-31	-9,367	USD	90
2018-04-01 to 2018-06-30	-6,408	USD	91
2018-01-01 to 2018-06-30	-15,711	USD	181
2018-01-01 to 2018-03-31	-9,303	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-01-01 to 2019-06-30	-5,025	USD	181
2018-01-01 to 2018-06-30	-4,585	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2019-01-01 to 2019-06-30	5,000	USD	181
2018-01-01 to 2018-06-30	4,200	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2019-06-30	-326,412	USD
At 2018-12-31	-310,314	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	708,000	shares	91
2019-01-01 to 2019-06-30	708,000	shares	181
2018-04-01 to 2018-06-30	708,000	shares	91
2018-01-01 to 2018-06-30	708,000	shares	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	-2,710	USD	91
2019-01-01 to 2019-06-30	-8,125	USD	181
2018-04-01 to 2018-06-30	-2,610	USD	91
2018-01-01 to 2018-06-30	-8,185	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2019-06-30	107	USD
At 2018-12-31	132	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	4,021	USD	91
2019-01-01 to 2019-06-30	7,973	USD	181
2018-04-01 to 2018-06-30	3,798	USD	91
2018-01-01 to 2018-06-30	7,526	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2019-06-30	300,663	USD
At 2018-12-31	284,590	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2019-06-30	10,800	USD
At 2018-12-31	7,700	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	2,710	USD	91
2019-01-01 to 2019-06-30	8,125	USD	181
2018-04-01 to 2018-06-30	2,610	USD	91
2018-01-01 to 2018-06-30	8,185	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2019-06-30	708,000	shares
At 2018-12-31	708,000	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2019-06-30	25,148	USD
At 2018-12-31	25,148	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2019-04-01 to 2019-06-30	2,710	USD	91
2019-01-01 to 2019-06-30	8,125	USD	181
2018-04-01 to 2018-06-30	2,610	USD	91
2018-01-01 to 2018-06-30	8,185	USD	181

Inspect the source

Entity: SKINOVATION PHARMACEUTICAL INCORPORATED / CIK 0001118072
Captured: 2026-09-21 17:18 UTC
SEC response SHA-256: 2a8f12373902fb089789064a50866081690b54ca91a66a8d71a686a973e9e781

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001118072.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))